维普期刊资源整合服务平台（V6.5）

33篇 您的检索式：作者名="DIENSTMANN R"

选中清除导出查看参考文献查看引证文献引用追踪共2页首页上一页第1页下一页末页 /2 跳转

	题名	作者	年代	出处	被引量
1	Drug development to overcome resistance to EGFR inhibitors in lung and colorectal caner 显示文摘	Dienstmann R de Dosso S Felip E	2012	Mol Oncol2012，6，1：	1
2	Targeting the PI3K/Akt/mTOR pathway–beyond rapalogs显示文摘	Markman B Dienstmann R Tabernero J	2010	Oncotarget2010，1，7：	1
3	Targeting thePI3K/Akt/mT0R pathway-beyond rapalogs 显示文摘	Markman B Dienstmann R Tabernero J	2010	Oncotarget2010，1，：	1
4	Drug development to overcome resistance to EGFR inhibitors in lung and colorectal caner显示文摘	Dienstmann R de Dosso S Felip E	2012	Mol Oncol2012，6，1：	1
5	The consensus molecular subtypes of colorectal cancer显示文摘	Guinney J Dienstmann R Wang X	2015	Nat Med2015，21，11：	1
6	Targeting the PI3K/Akt/mTOR pathway-beyond rapalogs 显示文摘	Markman B Dienstmann R Tabemero J	2010	Oncotarget2010，1，7：	1
7	Personalizing therapy with tar- geted agents in non-small cell lung cancer 显示文摘	Dienstmann R Martinez P Felip E	2011	Oncotarget2011，2，3：	1
8	Genomic aberra- tions in the FGFR pathway: opportunities for targeted therapies in solid tumors显示文摘	Dienstmann R Rodon J Prat A	2014	Ann Oncol2014，25，3：	1
9	Drug development to overcome resistance to EGFR inhibitors in lung and colorectal cancer显示文摘	Dienstmann R De Dosso S Felip E	2012	Mol Oncol2012，6，1：	1
10	The consensus molecular subtypes of eoloreetal cancer 显示文摘	Guinney J Dienstmann R Wang X	2015	Nat Med2015，21，11：	1
11	Picking the point of inhibition:a comparative review of PI3K/AKT/mTOR pathway inhibitors 显示文摘	DIENSTMANN R RODON J SERRA V	2014	Mol Cancer Ther2014，13，5：	1
12	Safety andPharmcieokinetics/tiarmacodynaniics of the First-in-ClassDual Action HER3/EGFR Antibody MEHD7945A in lo-cally Advanced or Metastatic Epithelial Tumors显示文摘	Juric D Dienstmann R Cervantes A	2015	ClinCancer Res2015，21，11：	1
13	Development ofPI3K inhibitors: lessons learned from early clinical trials显示文摘	Rodon J Dienstmann R Serra V	2013	Nat Rev Clin Oncol2013，10，3：	1
14	Development of molecular biomarkers in individualized treatment of colorectal canc- er显示文摘	De Mattos-Arruda L Dienstmann R Tabernero J	2011	Clin Colorectal Cancer2011，10，4：	1
15	Genomic aherrations in the FGFR pathway: opportunities for targeted therapies in solid tumors显示文摘	Dienstmann R RodonJ Prat A at al	2014	Ann Oncol2014，25，3：	1
16	Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs 显示文摘	DIENSTMANN R BRANA I RODON J	2011	Oncologist2011，16，12：	1
17	Drug deve- lopment to overcome resistance to EGFR inhibitors in lungand colorectal cancer 显示文摘	DIENSTMANN R DE DOSSO S] FELIP E	2012	Mol 0ncol2012，6，1：	1
18	Personalizing therapy with targeted agents in non-small cell lung cancer 显示文摘	DIENSTMANN R MARTINEZ P FELIP E	2011	Oncotarget2011，2，3：	1
19	BRAF as a target for eaneer lhera-py显示文摘	Dienstmann R Tabernero J	2011	Antieaneer Agents Med Chem2011，11，3：	1
20	Drug develop- ment to overcome resistance to EGFR inhibitors in lung and color- eetal cancer显示文摘	DIENSTMANN R DOSSO S D FELIP E	2012	Mol Oncol2012，6，1：	1

返回顶部每页显示：

共2页首页上一页第1页下一页末页 /2 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示